
GSK and Empirico Partner on First-in-Class Oligonucleotide for Respiratory Diseases
Gsk Partnership to advance first-in-class siRNA therapy for COPD and other respiratory diseases. GSK plc and Empirico Inc. (Empirico), a clinical-stage biotechnology company with leading capabilities in human genetics-driven target…












